Researchers at the University of Kentucky's Sanders-Brown Center on Aging have discovered that the chronic sleep loss plaguing Alzheimer's patients is caused by the brain's own overactive immune cells, not by the amyloid plaques those cells are responding to, and that silencing these immune cells restored more than two hours of restorative sleep per night in an animal model without clearing a single plaque from the brain.
The study, led by Shannon L. Macauley, Ph.D., an associate professor of physiology at the UK College of Medicine, and first author Nicholas J. Constantino, was published in Alzheimer's & Dementia with a university press release issued July 16, 2026, and wider media coverage beginning July 20.
Why This Matters
Between 25% and nearly half of all Alzheimer's patients experience significant, clinically disabling sleep disruption. It is one of the disease's most debilitating symptoms and one of the leading reasons caregivers report exhaustion, burnout, and the decision to pursue residential care for a loved one. For decades, the prevailing assumption has been that sleep loss in Alzheimer's is a downstream consequence of amyloid plaque accumulation: as plaques build up, they disrupt the brain circuits that regulate sleep.
This study overturns that assumption. The researchers found that it is not the plaques themselves but the inflammatory response of the brain's immune cells, called microglia, to those plaques that disrupts sleep. More strikingly, when they experimentally silenced 87% of those immune cells using a drug, mice with Alzheimer's pathology recovered more than two hours of restorative NREM sleep per night, even though every amyloid plaque in their brains remained. The plaques were still there. The sleep came back.
This distinction matters enormously for treatment. Current FDA-approved anti-amyloid therapies like lecanemab (Leqembi) and donanemab (Kisunla) target the plaques themselves. If sleep disruption is caused by the microglial inflammatory response rather than the plaques directly, then reducing amyloid may not be sufficient to restore sleep. A different, neuroinflammation-targeted intervention may be needed.
What We Know So Far
The research team used a well-established mouse model of Alzheimer's disease, the APPswe/PSEN1dE9 (APP/PS1) model, and performed EEG and EMG recordings to measure sleep architecture at different stages of disease progression.
Key findings from the published study:
Amyloid plaques caused NREM sleep loss, but the degree of sleep disruption did not worsen as plaque burden increased. This was the first clue that the plaques themselves were not the primary driver. The researchers then used whole-brain light-sheet microscopy to map both amyloid burden and microglial density simultaneously and found that microglial expansion into brain regions with little or no amyloid buildup preceded and predicted sleep disruption.
The most striking finding came from the microglial depletion experiment. Using a drug that targets the CSF1R receptor, the team depleted 87% of microglia in the Alzheimer's mice. The result: those mice gained more than two full hours of NREM sleep per night, with restorative sleep bouts that were significantly longer. The amyloid plaques were unaffected.
The University of Kentucky press release used a vivid analogy to describe the finding: "Amyloid plaques, sticky protein clumps that build up in the brain, are the fire in the kitchen. Microglia, the brain's resident immune cells, are the sprinklers. A mechanism designed to protect the body ends up hurting it."
Where This Research Stands in the Clinical Pathway
This is a study in an animal model of Alzheimer's disease. The mice used carry genetic mutations that cause amyloid plaque buildup, but they are not human beings, and the mechanisms of Alzheimer's in mice do not fully replicate the human disease. Translating findings from this model to human patients requires clinical trials.
Equally important: the drug used to deplete microglia in this experiment targets the CSF1R receptor and causes significant microglial reduction throughout the brain. Microglia also perform essential immune surveillance and housekeeping functions in the brain, and chronic depletion of the entire population would not be a viable clinical approach. The research points toward the need for more targeted strategies that dampen overactive microglial inflammation without eliminating microglia entirely.
"These findings position sleep and EEG-based network measures as sensitive, functional biomarkers of early Alzheimer's disease and support microglia as a therapeutic target to restore sleep during presymptomatic stages," the published study concludes.
What Doctors and Experts Say
Dr. Macauley, the study's senior author, explained the finding to the EurekAlert press release using the sprinkler analogy: when microglia respond to amyloid plaques by becoming chronically overactivated, they flood the brain with inflammatory signals that keep the brain in a heightened arousal state, preventing the deep NREM sleep it needs for waste clearance, memory consolidation, and repair. The study identifies this overactivation, not the plaques themselves, as the causal mechanism.
The research was funded by the BrightFocus Foundation (R01AG068330, R01AG093847), the NIH (P30AG072946), the NIH COBRE in CNS Metabolism (P20GM148326), and Cure Alzheimer's Fund.
What the Evidence Shows and What It Does Not
MedicalDaily Evidence Check
- Study type: Preclinical mouse model study using EEG/EMG sleep recording, light-sheet microscopy, and pharmacological microglial depletion
- Published in: Alzheimer's & Dementia (Wiley); doi: 10.1002/alz.71579
- Institution: University of Kentucky Sanders-Brown Center on Aging
- Senior author: Shannon L. Macauley, Ph.D., Associate Professor of Physiology; first author: Nicholas J. Constantino
- Press release date: July 16, 2026 (EurekAlert/UKNow); wider media pickup July 20
- Key finding: Microglial depletion (87%) restored over 2 hours of NREM sleep per night in Alzheimer's mice without clearing amyloid plaques; plaque burden alone did not worsen sleep loss once established
- Animal model used: APPswe/PSEN1dE9 (APP/PS1); female mice at 6 and 18 months of age
- Intervention: CSF1R-mediated microglial depletion
- What it shows: Microglia, not amyloid plaques directly, appear to be the causal driver of NREM sleep loss in this Alzheimer's model
- What it does not prove: That this mechanism applies identically in humans; that total microglial depletion is a viable or safe clinical strategy; that targeting microglia in Alzheimer's patients will restore sleep without adverse effects
- What readers should know: This finding adds to the scientific understanding of Alzheimer's-related sleep disruption and may guide future drug development, but it does not offer an immediate treatment for patients
Who Should Pay Attention?
This research is most directly relevant to:
- Alzheimer's patients and their families and caregivers, for whom sleep disruption is a daily burden
- Neurologists, geriatricians, and sleep medicine specialists treating Alzheimer's patients who struggle with sleep
- Researchers working on neuroinflammation, microglia-targeted therapies, or Alzheimer's biomarkers
- Pharmaceutical developers exploring anti-neuroinflammatory approaches as Alzheimer's disease-modifying or symptom-modifying strategies
For patients currently taking anti-amyloid therapies like Leqembi or Kisunla, this finding does not mean those therapies are wrong or should be stopped. They address a different target for a different purpose.
Symptoms This Research Addresses
The sleep disruption in Alzheimer's that this study specifically targets includes:
- Difficulty staying asleep (fragmented sleep with frequent awakenings)
- Reduced NREM (non-rapid eye movement) sleep, the deep restorative stage critical for brain waste clearance and memory consolidation
- Daytime drowsiness that impairs cognitive function and safety
- Night wandering, which is a major caregiver challenge and safety risk
These symptoms appear early in the disease course, often before significant memory loss becomes apparent, and the study's findings suggest they could potentially be targeted even in the presymptomatic phase if microglial-targeted interventions are developed and validated.
What You Can Do Now
- Alzheimer's patients struggling with sleep should discuss sleep management with their neurologist or geriatrician. Current options include sleep hygiene improvements, behavioral interventions, and in some cases medications.
- Caregivers managing a loved one's nighttime wakefulness should ask about referral to a sleep medicine specialist familiar with neurodegenerative disease.
- This research does not change current clinical treatment guidelines. Patients on anti-amyloid therapies should not change their treatment based on this finding.
- Families interested in Alzheimer's sleep research developments can follow the Alzheimer's Association (alz.org) and the Sanders-Brown Center on Aging at the University of Kentucky for updates on this line of research.
- For broader Alzheimer's treatment discussions, the Alzheimer's Association and the National Institute on Aging maintain updated patient and caregiver resources.
Cost and Access: What Patients Should Know
No clinical treatment based on this specific finding is currently available. Sleep aids and behavioral sleep interventions for Alzheimer's patients are covered by most insurance plans when prescribed. For caregivers experiencing burnout related to nighttime wakefulness, the Alzheimer's Association offers a 24/7 helpline (1-800-272-3900) and caregiver support programs.
What Happens Next
The University of Kentucky team will pursue follow-up research on more targeted microglial modulation strategies, as full microglial depletion is not a viable clinical approach. The research opens a new avenue for neuroinflammation-targeted drug development for Alzheimer's sleep symptoms. Clinical translation will require identification of a suitable drug target on microglia that can be modulated selectively, followed by Phase 1 and Phase 2 safety and efficacy trials in human patients. MedicalDaily will report on significant advances in this research program.
The Bottom Line
University of Kentucky researchers have found that overactive microglia, not amyloid plaques, are the direct cause of the sleep loss that affects 25 to 45 percent of Alzheimer's patients. Silencing 87% of these brain immune cells in an animal model restored more than two hours of restorative NREM sleep per night without removing a single plaque. This finding has direct implications for drug development and may explain why plaque-targeting therapies have not been shown to improve sleep in Alzheimer's patients. Clinical application is years away, but the mechanistic discovery identifies a specific, potentially targetable pathway for one of Alzheimer's most burdensome symptoms.
